Deans' stroke musings: Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, September 23, 2022

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals

Since your cerebral blood flow went to hell during your stroke, what EXACTLY has your doctor done to normalize it since then and prevent this problem from happening?

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals

Jarith L Ebenau, Denise Visser, Sander C J Verfaillie, Tessa Timmers

Eur J Nucl Med Mol Imaging. 2022 Sep 8 [Epub ahead of print]

PURPOSE The role of cerebral blood flow (CBF) in the early stages of Alzheimer's disease is complex and largely unknown. We investigated cross-sectional and longitudinal associations between CBF, amyloid burden, and cognition, in cognitively normal individuals with subjective cognitive decline (SCD). METHODS We included 187 cognitively normal individuals with SCD from the SCIENCe project (65 ± 8 years, 39% F, MMSE 29 ± 1). Each underwent a dynamic (0-70 min) [¹⁸F]florbetapir PET and T1-weighted MRI scan, enabling calculation of mean binding potential (BP_ND; specific amyloid binding) and R₁(measure of relative (r)CBF). Eighty-three individuals underwent a second [¹⁸F]florbetapir PET (2.6 ± 0.7 years). Participants annually underwent neuropsychological assessment (follow-up time 3.8 ± 3.1 years; number of observations n = 774). RESULTS A low baseline R₁was associated with steeper decline on tests addressing memory, attention, and global cognition (range betas 0.01 to 0.27, p